EMEA-002007-PIP02-17-M02
Key facts
| Invented name |
Libtayo
|
| Active substance |
Cemiplimab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0179/2022
|
| PIP number |
EMEA-002007-PIP02-17-M02
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Regeneron Ireland DAC
E-mail: clinicaltrials@regeneron.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|